Elan Financial Statements
Elan Financial Information
| Company Type | Public Headquarters |
|---|---|
| Fiscal Year-End | December |
| Annual Report | Company Web Site |
| Investor Relations | Company Web Site |
This data is provided as per license from EDGAR Online
Elan Income Statement
| 2007 | 2006 | 2005 | |
|---|---|---|---|
| Revenue ($ mil.) | 759.4 | 560.4 | 490.3 |
| Gross Profit ($ mil.) | 421.5 | 349.2 | 294.2 |
| Operating Income ($ mil.) | (265.3) | (166.4) | (198.5) |
| Total Net Income ($ mil.) | (405.0) | (267.3) | (383.6) |
| Diluted EPS (Net Income) | -- | -- | -- |
Elan Financial Ratios
| Company | Industry Median |
Market Median1 |
|
|---|---|---|---|
| Price/Sales Ratio | 24.68 | 3.69 | 1.58 |
| Price/Earnings Ratio | -- | 15.88 | 15.68 |
| Price/Book Ratio | 162.53 | 2.70 | 1.50 |
| Price/Cash Flow Ratio | -- | 11.61 | 9.70 |
1 Public companies trading on the New York Stock Exchange, the American Stock Exchange, and the NASDAQ National Market.
Detailed Elan Financial Ratios
Elan Competitive Intelligence
| Bayer Schering Pharma | Merck Serono | Pfizer | |
|---|---|---|---|
| Annual Sales ($ mil.) | 6,286.8 | 2,586.4 | 48,418.0 |
| Employees | 25,037 | 4,826 | 86,600 |
| Market Cap ($ mil.) | -- | -- | 117,240.9 |
Competitive Landscape
